Oncology & Cancer

Understanding the mechanism behind melanoma resistance to treatment

In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered that a factor secreted by tumor cells is responsible for the resistance. These findings ...

Oncology & Cancer

Drug reprograms immune responses to target glioblastoma

Investigators from Northwestern University Feinberg School of Medicine and The University of Texas MD Anderson Cancer Center have discovered that using a novel drug to target the STING pathway in glioblastoma reprogrammed ...

Oncology & Cancer

Improving cancer immunotherapy by prolonging T-cell survival

In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment for 15 cancers, including melanoma and some types of lymphomas ...

page 2 from 40